BIOHIT OYJ STOCK EXCHANGE RELEASE 18 MARCH 2010 AT 3:20 PM CHANGES IN BIOHIT OYJ'S MANAGEMENT TEAM Biohit Oyj's Financial Director Petteri Rehu has resigned as of 1st April 2010. Controller Eija Patrikainen will take over the duties temporarily until the position has been filled. MSc (econ.), Terhi Lampén (37) has been appointed Nordic Sales Manager and a Member of the Management Team of Biohit's Diagnostics Business as of 18th March 2010. Ms Lampén will replace Päivi Siltala, who has resigned from the company. Prior to joining Biohit, Lampén has been working several years with Johnson & Johnson as a Product Specialist of Medical Devices. Further information: Osmo Suovaniemi, M.D., Ph.D., Professor President & CEO Tel: +358-9-773 861 GSM: +358-40-745 5605 Email: osmo.suovaniemi@biohit.com Distribution: NASDAQ OMX Helsinki Oy Central storage facility (www.oam.fi) Press www.biohit.com About Biohit Oyj Established in 1988, Biohit Oyj is a Finnish biotechnology company quoted on the NASDAQ OMX Helsinki since 1999. It applies a determined and persistent innovation and patenting strategy in its operations. In cooperation with scientific communities, Biohit produces new technology, products and services based on research results and innovations for the development of safe and cost-effective liquid handling in laboratories as well as the early diagnosis and prevention of gastrointestinal tract diseases Biohit is divided into liquid handling and diagnostics business units. Liquid handling products include electronic and mechanical pipettes and dispensers, and disposable tips, as well as pipette maintenance and calibration services for use by research institutions, healthcare and industrial laboratories. The diagnostics business comprises products and analysis systems for the early detection of gastrointestinal diseases, such as the blood-sample based GastroPanel and GastroView, for diagnosing diseases of the stomach and associated risks, quick tests for the diagnosis of lactose intolerance, Helicobacter pylori infection and ColonView for the early detection of faecal occult blood. The Acetium capsule, developed to eliminate carcinogenic acetaldehyde in the gastrointestinal tract, is part of the strategic R&D work of the diagnostics business unit, whose main objective is the prevention of gastrointestinal diseases. Biohit Group employs a staff of approximately 370 in 9 countries. The company is headquartered in Finland and has subsidiaries in France, Germany, the UK, Russia, India, China, Japan and the USA. Biohit's products are sold by approximately 450 distributors in 70 countries. Biohit's share (BIOBV) is quoted on the NASDAQ OMX Helsinki Small cap/Healthcare. Read more at www.biohit.com.